EFFICACY AND SAFETY OF AGOMELATINE IN TREATMENT OF MAJOR DEPRESSIVE DISORDER: A PILOT STUDY

EFFICACY AND SAFETY OF AGOMELATINE IN TREATMENT OF MAJOR DEPRESSIVE DISORDER: A PILOT STUDY

Back ground: Agomelatine is a novel antidepressant which acts through a combination of agonistic actions at MT1 and MT2 subtypes of Melatonergic receptors and antagonistic actions at 5-HT2C subtype of serotonergic receptors. Objective: The study was carried out to evaluate the efficacy and safety of...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of pharmaceutical sciences and research 2016-08, Vol.7 (8), p.3517-3517
Hauptverfasser: Nukala, Srikrishna, Komaram, Ravi Babu, Palla, Jayasree, Murthy, K S N
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 3517
container_issue 8
container_start_page 3517
container_title International journal of pharmaceutical sciences and research
container_volume 7
creator Nukala, Srikrishna
Komaram, Ravi Babu
Palla, Jayasree
Murthy, K S N
description Back ground: Agomelatine is a novel antidepressant which acts through a combination of agonistic actions at MT1 and MT2 subtypes of Melatonergic receptors and antagonistic actions at 5-HT2C subtype of serotonergic receptors. Objective: The study was carried out to evaluate the efficacy and safety of Agomelatine in the treatment of Major depressive disorder. Method: A prospective study was conducted at outpatient department of Psychiatry, GSL Medical College & General hospital Rajahmundry, 76 outpatients between 18 to 65 yrs of age of either sex, who met DSM-IV-TR criteria for major depressive disorder and had a minimum depression score of 20 on HAM-D17 were assigned to 8weeks of treatment with Agomelatine (25-50 mg/day). The main efficacy outcome measured was HAM-D17 total score (change from baseline to last post-baseline assessment of 8 weeks). Secondary outcome measures were assessed on Clinical Global Impression- severity (CGI-S) and Clinical Global Impression-improvement (CGI-I) scales. Results: The study results showed that Agomelatine was effective in Major depressive disorder. HAM-D17 score reduced effectively from baseline to end of week 8 (p
doi_str_mv 10.13040/IJPSR.0975-8232.7(8).3517-21
format Article
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_miscellaneous_1815711176</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1815711176</sourcerecordid><originalsourceid>FETCH-LOGICAL-p118t-789b40f50384a1862843028e12157a46f44468a61585108615fd2e5c39af11d23</originalsourceid><addsrcrecordid>eNo9jktLw0AYRQdBsNT-h9kIdZE43zySibshmdQpeZFMheCixDYBJdrqtP-_EcW7OYsL516E7oD4wAgnD2ZdNbVPolB4kjLqh0t57zMBoUfhCs3-ixu0cO6dTAkogGQz9KLT1MQqbrEqEtyoVNsWlylWqzLXmbKm0NgU2NZa2VwX9qfL1bqscaKrWjeNedY4MU1ZJ7p-xApXJistbuwmaW_R9dCNrl_8cY42kz5-8rJyNW1m3nH6cPJCGb1yMgjCJO9ABlRyRqjsgYIIOx4MnPNAdgEIKYDIicOe9mLHom4A2FM2R8tf7_H78HXu3Wn78eZ2_Th2n_3h7LYgJxEAhAG7AKkVTYw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1815711176</pqid></control><display><type>article</type><title>EFFICACY AND SAFETY OF AGOMELATINE IN TREATMENT OF MAJOR DEPRESSIVE DISORDER: A PILOT STUDY</title><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Nukala, Srikrishna ; Komaram, Ravi Babu ; Palla, Jayasree ; Murthy, K S N</creator><creatorcontrib>Nukala, Srikrishna ; Komaram, Ravi Babu ; Palla, Jayasree ; Murthy, K S N</creatorcontrib><description>Back ground: Agomelatine is a novel antidepressant which acts through a combination of agonistic actions at MT1 and MT2 subtypes of Melatonergic receptors and antagonistic actions at 5-HT2C subtype of serotonergic receptors. Objective: The study was carried out to evaluate the efficacy and safety of Agomelatine in the treatment of Major depressive disorder. Method: A prospective study was conducted at outpatient department of Psychiatry, GSL Medical College &amp; General hospital Rajahmundry, 76 outpatients between 18 to 65 yrs of age of either sex, who met DSM-IV-TR criteria for major depressive disorder and had a minimum depression score of 20 on HAM-D17 were assigned to 8weeks of treatment with Agomelatine (25-50 mg/day). The main efficacy outcome measured was HAM-D17 total score (change from baseline to last post-baseline assessment of 8 weeks). Secondary outcome measures were assessed on Clinical Global Impression- severity (CGI-S) and Clinical Global Impression-improvement (CGI-I) scales. Results: The study results showed that Agomelatine was effective in Major depressive disorder. HAM-D17 score reduced effectively from baseline to end of week 8 (p&lt;0.05). The percentage of responders and remitters at end of week 8 were 56.57% and 26.31% respectively. The mean CGI-S and CGI-I scores improved from baseline to end of week 8 (P&lt;0.05). Conclusion: Agomelatine as a novel agent with a unique pharmacological profile, showed good efficacy in reducing the symptoms of Major depressive disorder.</description><identifier>EISSN: 0975-8232</identifier><identifier>DOI: 10.13040/IJPSR.0975-8232.7(8).3517-21</identifier><language>eng</language><ispartof>International journal of pharmaceutical sciences and research, 2016-08, Vol.7 (8), p.3517-3517</ispartof><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Nukala, Srikrishna</creatorcontrib><creatorcontrib>Komaram, Ravi Babu</creatorcontrib><creatorcontrib>Palla, Jayasree</creatorcontrib><creatorcontrib>Murthy, K S N</creatorcontrib><title>EFFICACY AND SAFETY OF AGOMELATINE IN TREATMENT OF MAJOR DEPRESSIVE DISORDER: A PILOT STUDY</title><title>International journal of pharmaceutical sciences and research</title><description>Back ground: Agomelatine is a novel antidepressant which acts through a combination of agonistic actions at MT1 and MT2 subtypes of Melatonergic receptors and antagonistic actions at 5-HT2C subtype of serotonergic receptors. Objective: The study was carried out to evaluate the efficacy and safety of Agomelatine in the treatment of Major depressive disorder. Method: A prospective study was conducted at outpatient department of Psychiatry, GSL Medical College &amp; General hospital Rajahmundry, 76 outpatients between 18 to 65 yrs of age of either sex, who met DSM-IV-TR criteria for major depressive disorder and had a minimum depression score of 20 on HAM-D17 were assigned to 8weeks of treatment with Agomelatine (25-50 mg/day). The main efficacy outcome measured was HAM-D17 total score (change from baseline to last post-baseline assessment of 8 weeks). Secondary outcome measures were assessed on Clinical Global Impression- severity (CGI-S) and Clinical Global Impression-improvement (CGI-I) scales. Results: The study results showed that Agomelatine was effective in Major depressive disorder. HAM-D17 score reduced effectively from baseline to end of week 8 (p&lt;0.05). The percentage of responders and remitters at end of week 8 were 56.57% and 26.31% respectively. The mean CGI-S and CGI-I scores improved from baseline to end of week 8 (P&lt;0.05). Conclusion: Agomelatine as a novel agent with a unique pharmacological profile, showed good efficacy in reducing the symptoms of Major depressive disorder.</description><issn>0975-8232</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNo9jktLw0AYRQdBsNT-h9kIdZE43zySibshmdQpeZFMheCixDYBJdrqtP-_EcW7OYsL516E7oD4wAgnD2ZdNbVPolB4kjLqh0t57zMBoUfhCs3-ixu0cO6dTAkogGQz9KLT1MQqbrEqEtyoVNsWlylWqzLXmbKm0NgU2NZa2VwX9qfL1bqscaKrWjeNedY4MU1ZJ7p-xApXJistbuwmaW_R9dCNrl_8cY42kz5-8rJyNW1m3nH6cPJCGb1yMgjCJO9ABlRyRqjsgYIIOx4MnPNAdgEIKYDIicOe9mLHom4A2FM2R8tf7_H78HXu3Wn78eZ2_Th2n_3h7LYgJxEAhAG7AKkVTYw</recordid><startdate>20160801</startdate><enddate>20160801</enddate><creator>Nukala, Srikrishna</creator><creator>Komaram, Ravi Babu</creator><creator>Palla, Jayasree</creator><creator>Murthy, K S N</creator><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope></search><sort><creationdate>20160801</creationdate><title>EFFICACY AND SAFETY OF AGOMELATINE IN TREATMENT OF MAJOR DEPRESSIVE DISORDER: A PILOT STUDY</title><author>Nukala, Srikrishna ; Komaram, Ravi Babu ; Palla, Jayasree ; Murthy, K S N</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p118t-789b40f50384a1862843028e12157a46f44468a61585108615fd2e5c39af11d23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><toplevel>online_resources</toplevel><creatorcontrib>Nukala, Srikrishna</creatorcontrib><creatorcontrib>Komaram, Ravi Babu</creatorcontrib><creatorcontrib>Palla, Jayasree</creatorcontrib><creatorcontrib>Murthy, K S N</creatorcontrib><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>International journal of pharmaceutical sciences and research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nukala, Srikrishna</au><au>Komaram, Ravi Babu</au><au>Palla, Jayasree</au><au>Murthy, K S N</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>EFFICACY AND SAFETY OF AGOMELATINE IN TREATMENT OF MAJOR DEPRESSIVE DISORDER: A PILOT STUDY</atitle><jtitle>International journal of pharmaceutical sciences and research</jtitle><date>2016-08-01</date><risdate>2016</risdate><volume>7</volume><issue>8</issue><spage>3517</spage><epage>3517</epage><pages>3517-3517</pages><eissn>0975-8232</eissn><abstract>Back ground: Agomelatine is a novel antidepressant which acts through a combination of agonistic actions at MT1 and MT2 subtypes of Melatonergic receptors and antagonistic actions at 5-HT2C subtype of serotonergic receptors. Objective: The study was carried out to evaluate the efficacy and safety of Agomelatine in the treatment of Major depressive disorder. Method: A prospective study was conducted at outpatient department of Psychiatry, GSL Medical College &amp; General hospital Rajahmundry, 76 outpatients between 18 to 65 yrs of age of either sex, who met DSM-IV-TR criteria for major depressive disorder and had a minimum depression score of 20 on HAM-D17 were assigned to 8weeks of treatment with Agomelatine (25-50 mg/day). The main efficacy outcome measured was HAM-D17 total score (change from baseline to last post-baseline assessment of 8 weeks). Secondary outcome measures were assessed on Clinical Global Impression- severity (CGI-S) and Clinical Global Impression-improvement (CGI-I) scales. Results: The study results showed that Agomelatine was effective in Major depressive disorder. HAM-D17 score reduced effectively from baseline to end of week 8 (p&lt;0.05). The percentage of responders and remitters at end of week 8 were 56.57% and 26.31% respectively. The mean CGI-S and CGI-I scores improved from baseline to end of week 8 (P&lt;0.05). Conclusion: Agomelatine as a novel agent with a unique pharmacological profile, showed good efficacy in reducing the symptoms of Major depressive disorder.</abstract><doi>10.13040/IJPSR.0975-8232.7(8).3517-21</doi><tpages>1</tpages></addata></record>
fulltext fulltext
identifier EISSN: 0975-8232
ispartof International journal of pharmaceutical sciences and research, 2016-08, Vol.7 (8), p.3517-3517
issn 0975-8232
language eng
recordid cdi_proquest_miscellaneous_1815711176
source EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
title EFFICACY AND SAFETY OF AGOMELATINE IN TREATMENT OF MAJOR DEPRESSIVE DISORDER: A PILOT STUDY
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T05%3A44%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=EFFICACY%20AND%20SAFETY%20OF%20AGOMELATINE%20IN%20TREATMENT%20OF%20MAJOR%20DEPRESSIVE%20DISORDER:%20A%20PILOT%20STUDY&rft.jtitle=International%20journal%20of%20pharmaceutical%20sciences%20and%20research&rft.au=Nukala,%20Srikrishna&rft.date=2016-08-01&rft.volume=7&rft.issue=8&rft.spage=3517&rft.epage=3517&rft.pages=3517-3517&rft.eissn=0975-8232&rft_id=info:doi/10.13040/IJPSR.0975-8232.7(8).3517-21&rft_dat=%3Cproquest%3E1815711176%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1815711176&rft_id=info:pmid/&rfr_iscdi=true